Panax ginseng C.A. Meyer, root
Cold-pressed juice from an aseptically grown ginseng root. No heat, no solvent, no drying step. The complete native profile of the root, in the proportions the plant produced it.
Positioned for anti-aging, on the cellular longevity axis. The first preclinical data measured on this material are below.
What is it
The root is harvested from a sealed cleanroom and pressed within hours, without drying and without steaming. The juice is clarified by sterile filtration and standardized by HPLC on every batch. Most botanical actives are a fraction pulled out of the plant and rebuilt in a carrier. This one is the plant, stabilized for shelf life without propylene glycol.
The published literature on Panax ginseng was almost entirely built on dried, steamed or fermented root. Steaming converts the polar ginsenosides into deglycosylated forms and creates Maillard reaction products that fresh root does not contain. Nativome Ginseng is a different material from the one most of that literature describes.
FORM
CLARIFIED JUICE
INCLUSION
1 TO 3%
PRESERVATIVES
NONE
ORIGIN
BELGIUM
SIRT1 gene expression increased in a dose-dependent manner in human dermal fibroblasts. Extracellular vesicles from Panax ginseng have been reported to improve senescent phenotypes in the same cell type.
MEASURED ON NATIVOME GINSENG
1 study on this material, in vitro · 3 supporting studies on ginseng compounds
Upregulation of aquaporin 3, filaggrin, loricrin and hyaluronic acid synthases. Shown for compounds isolated from fresh ginseng root, and benchmarked against retinol.
SCIENTIFIC EVIDENCE
STRONG
6 studies cited, in vitro and in vivo animal
Inhibition of MMP-1 and modulation of the dermal matrix through Smad signaling. Replicated across independent groups and multiple cell lines.
SCIENTIFIC EVIDENCE
STRONG
9 studies cited, in vitro and in vivo animal
STRONG, replicated by independent groups in more than one model. MODERATE, shown by a single group or in a single model. EMERGING, mechanistic signal only. MEASURED ON NATIVOME GINSENG, generated on the material sold under this name.

SIRT1, DOSE-DEPENDENT, IN THREE INDEPENDENT EXPERIMENTS
Nativome Ginseng increases SIRT1 gene expression in adult human dermal fibroblasts. The response follows the dose in every experiment, and the three experiments agree with each other to within four percent at the active dose.
SIRT1 is one of the best-characterized nodes of the cellular longevity axis in skin. This is the first evidence generated on this material, rather than on the wider literature that surrounds the plant.

Adult human dermal fibroblasts, primary culture. 24 h treatment, 1% FBS.
RT-qPCR, GAPDH normalization, 2^-ddCt. Three independent experiments.
Three concentrations tested, equivalent to 0.05, 0.1 and 0.2% of Nativome Ginseng in the culture medium. Relative SIRT1 expression 1.04, 1.11 and 1.27.
p < 0.01 at the active dose. Study PKDERM, 2026. Full report released to qualified laboratories.
Botalys ginseng root juice reduced IL-6 release in human keratinocytes under inflammatory challenge, at every concentration tested below 0.2%, by up to 46%. Four of five Botalys root materials reduced IL-6 in the same study. Confirmation on Nativome Ginseng is in progress.

Human epidermal keratinocytes, PMA and calcium ionophore challenge. 24 h treatment.
IL-6 quantified by ELISA, normalized to cell viability. n = 3.
Study StratiCELL, 2024. Confirmation on Nativome Ginseng in progress.
Saponins, polysaccharides, phenolic acids, phytosterols and peptides, and the skin pathways each family acts on.
Evidence strength above reflects the published work on Panax ginseng root compounds, not on the Botalys ingredient itself. Studies conducted on Nativome Ginseng are reported separately and identified as such.
Human clinical work on ginseng is limited. A small number of studies with instrumental outcomes, twenty to twenty-three subjects, four to eight weeks, none of them on fresh root material. We publish this because a formulator will find it anyway.

FORMULATION
RECOMMENDED USE LEVELS
3% Hero SKU
Where the ingredient carries the claim.
2% Standard
Default inclusion across a range.
1% Floor
Formulation minimum, not an efficacy threshold.
The dose-response curve for this material is being established in preclinical study. Finished formula tolerance should be confirmed by the formulator.
Technical documentation and formulation samples are available to qualified laboratories.
REQUEST A SAMPLE


